Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Developments

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

Hirosaki University Hospital agreed to lease and utilize a Senhance Surgical System from Asensus Surgical (NYSE American: ASXC), which is digitizing the interface between surgeon and patient to enhance performance...

October 6, 2021

Developments

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange. The company’s common stock; 8% convertible debentures, with a maturity date...

October 5, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Developments

Lanier Biotherapeutics in license pact with Alloy Therapeutics

Newly formed antibody developer Lanier Biotherapeutics entered into a license agreement with Alloy Therapeutics, a closely held drug discovery company. Under the accord, Alloy will acquire the AbeoMouse and Direct...

October 5, 2021

Developments

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic...

September 30, 2021

Developments

FDA clears TransMedics transplant OCS Liver System

TransMedics Group (NASDAQ:TMDX) received premarket approval from the FDA of its OCS Liver System for use with organs from donors after brain and circulatory death. “We are extremely proud of this approval of our...

September 29, 2021

Developments

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

Hepion Pharmaceuticals (NASDAQ:HEPA) met all endpoints in a drug-drug-interaction study with its lead drug candidate, CRV431. The randomized, open label study was conducted in 24 healthy volunteers to determine if...

September 29, 2021

Developments

Altamira Therapeutics files Bentrio 510(k) for allergy indication

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio is an OTC nasal spray that is drug- and preservative-free and designed to provide triple protection against airborne viruses and allergens. First, it helps to protect the...

September 27, 2021

Developments

Tryp Therapeutics files IND for Phase 2a eating disorders study

Tryp Therapeutics (CSE TRYP; OTCQB:TRYPF) submitted an IND with the FDA to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders. The trial is being conducted...

September 23, 2021

Developments

Cognetivity Neurosciences to place ICA system in Dubai

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) reached its first commercial agreement for the Integrated Cognitive Assessment (ICA) to be deployed at the Clemenceau Medical Center (CMC) in Dubai. CMC is...

September 22, 2021

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Health Canada clears first-in-man study of OpSens guidewire

OpSens (TSX:OPS; OTCQX:OPSSF) received Health Canada’s approval to begin a first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement (TAVR). ...

September 20, 2021

Developments

Heritage Cannabis launches first Opticann CB4 medical products in Canada

Heritage Cannabis (CSE:CANN; OTCQX:HERTF) announced that Opticann, the medical brand and subsidiary of Heritage, is launching its first suite of CB4 branded products and has launched Opticann.ca in Canada...

September 20, 2021

Developments

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

atai Life Sciences (NASDAQ;ATAI) amended a loan agreement with IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) to support IntelGenx’s conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock...

September 15, 2021

Developments

Cognetivity’s ICA to be deployed in world-leading UK dementia care practice

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) agreed with Loveday & Co. to deploy the Integrated Cognitive Assessment (ICA) in the specialist dementia and senior care provider’s practice. Loveday is the only...

September 14, 2021

Developments

PharmaJet to deliver Scancell COVID-19 DNA vaccines

Closely held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection systems. ...

September 14, 2021

Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion Pharmaceuticals (NASDAQ:HEPA) is initiating a Phase 2b clinical trial after releasing additional positive efficacy data from its Phase 2a AMBITION trial with CRV431 for the treatment of non-alcoholic...

September 13, 2021

Developments

IntelGenx partner launches RIZAPORT for acute migraine in Spain

IntelGenx’s (TSXV:IGX; OTCQB:IGXT) commercialization partner in the EU, Exeltis Healthcare, launched RIZAPORT, a unique treatment of acute migraine, in Spain. RIZAPORT is based on IntelGenx’s...

September 8, 2021

Developments

111, Inc. in $10-million share repurchase program

The board of Shanghai-based 111, Inc. (NASDAQ:YI) authorized a share repurchase program of up to $10-million of the company’s Class A ordinary shares in the form of American depositary shares in the next 12 months. The...

September 7, 2021

Subscribe